Identification of Severe Eosinophilic Asthma in Primary Care
This Research Review E-Learning Module is intended for GPs and discusses characteristics associated with severe eosinophilic asthma, as well as clinical trial and real-world evidence for the use of anti-IL-5 therapy. It is based on a Research Review Educational Series publication entitled “Identification of Severe Eosinophilic Asthma in Primary Care”.
Before starting the module please read the Research Review Educational Series, accessed through the link below:
to access the quiz source material
Educational Series - Identification of Severe Eosinophilic Asthma in Primary Care
The PDF through the link above can be viewed on screen, saved and printed.
This E-Learning Module covers:
- Patient characteristics associated with severe eosinophilic asthma
- Practical advice for measurement of blood eosinophil count
- A checklist for referral of patients with severe eosinophilic asthma to a specialist
- Clinical trial and real-world evidence for anti-IL-5 therapy in severe eosinophilic asthma
After completing this module, you should have an improved understanding of how to:
- Assess phenotype in patients with severe asthma
- Measure blood eosinophils in patients with severe asthma
- Optimise initial management of patients with severe eosinophilic asthma
- Advise patients on the efficacy and safety of add-on therapy with an anti-IL-5 agent for the treatment of severe eosinophilic asthma
Expert commentary is provided by:
Dr Jeffrey Garrett, a specialist respiratory physician and active researcher who is currently involved in evaluating the use of biomarkers to direct asthma care more accurately.
Dr Andrew Corin, a GP and clinical researcher with extensive experience in governance roles for health and community organisations.
Module questions have been developed by Dr Chris Tofield, who works in primary care skin cancer treatment and as a consultant to Research Review.
“Identification of Severe Eosinophilic Asthma in Primary Care” E-Learning Module has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.
This module has been created with funding from GSK. The content is entirely independent and based on published studies and the authors' opinions.